Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Drugs In Development, 2021

Global Markets Direct’s, ‘Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) 2021‘, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics. The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. The report analyses the pipeline products from therapy areas under Gastrointestinal, Immunology and Infectious Disease development targeting Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

– The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

– The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aviara Pharmaceuticals Inc

C4X Discovery Holdings Plc

DiCE Molecules SV Inc

Genentech USA Inc

Gilead Sciences Inc

Morphic Therapeutic Inc

Polpharma Biologics SA

Progenity Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development

Aviara Pharmaceuticals Inc

C4X Discovery Holdings Plc

DiCE Molecules SV Inc

Genentech USA Inc

Gilead Sciences Inc

Morphic Therapeutic Inc

Polpharma Biologics SA

Progenity Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles

etrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-1427 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MORF-057 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTG-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha 4 Beta 1 and Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-10000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones

Featured News & Press Releases

Sep 07, 2021: Protagonist Therapeutics appoints Scott Plevy, M.D., executive vice president and therapeutic head, gastroenterology

Jul 09, 2021: Morphic reports new data from positive phase 1 study of MORF-057, oral integrin inhibitor candidate for IBD

Jul 02, 2021: Morphic Therapeutic to host analyst and investor call on July 9, 2021

May 28, 2021: Morphic Therapeutic to present positive phase 1 data for MORF-057 at ECCO’21 Virtual Congress

Mar 01, 2021: Morphic reports positive interim results from single ascending dose phase 1 clinical trial of MORF-057

Feb 22, 2021: Morphic Therapeutic to host analyst and investor call on March 1, 2021

Jan 19, 2021: Ready-to-use self-injectable formulation of ENTYVIO (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn's disease and ulcerative colitis

Dec 09, 2020: Takeda’s pipeline including vedolizumab has potential to contribute significantly to revenue growth over next decade

Oct 13, 2020: Takeda reports positive interim data from trial of Entyvio

Oct 12, 2020: Morphic announces presentation of new data supporting development of MORF-057 at UEG Week Virtual 2020

Sep 23, 2020: Morphic Therapeutic announces first healthy volunteers dosed in Phase 1 clinical trial of MORF-057

Sep 02, 2020: Update on the U.S. Development Program for the investigational subcutaneous formulation of ENTYVIO (vedolizumab) as a maintenance therapy in adults with moderate to severe Ulcerative Colitis

Aug 11, 2020: Roche announces mixed Phase III results of etrolizumab

Jun 23, 2020: Takeda receives U.S. FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at manufacturing facility in Brooklyn Park, Minnesota

May 08, 2020: European commission approves subcutaneous formulation of Entyvio (Vedolizumab) for use as maintenance therapy in adults with moderately to severely active Ulcerative Colitis or Crohn’s Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Aviara Pharmaceuticals Inc, 2021

Pipeline by C4X Discovery Holdings Plc, 2021

Pipeline by DiCE Molecules SV Inc, 2021

Pipeline by Genentech USA Inc, 2021

Pipeline by Gilead Sciences Inc, 2021

Pipeline by Morphic Therapeutic Inc, 2021

Pipeline by Polpharma Biologics SA, 2021

Pipeline by Progenity Inc, 2021

Pipeline by Protagonist Therapeutics Inc, 2021

Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Pipeline by Zealand Pharma AS, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports